Language Select


Recent News
May 10, 2017

Varian Medical Systems (NYSE: VAR) today announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam® system for proton therapy...

May 8, 2017

Varian Medical Systems (NYSE: VAR) has been selected by Proton International to install a Varian ProBeam® Compact single-room proton therapy system in a new cancer treatment center on the campus...

May 7, 2017

In front of a large crowd at the annual meeting of the European Society for Radiotherapy & Oncology (ESTRO 36) on May 6th, Varian Medical Systems (NYSE: VAR) unveiled the Halcyon™ system, an...

More news >

Recent Blog Posts
May 8, 2017Spot ON
Do you have challenging cases demonstrating innovative treatment plans for IMPT that you would like to share with your peers? Varian is excited to sponsor a publishing competition presented by Cureus Journal of Medical Science.
Read more
Apr 25, 2017Spot ON
Varian’s Particle Therapy division will be showcasing the latest in proton therapy solutions at the Annual Meetings of ESTRO and PTCOG in May.
Read more
Apr 11, 2017Spot ON
The University of Texas MD Anderson Cancer Center recently presented data at the 2017 Multidisciplinary Thoracic Cancers Symposium which shows early promise for the treatment of recurrent lung cancer with advanced form of proton therapy.
Read more
Corporate Communications Contacts
Spencer Sias
Vice President, Corporate Communications and Investor Relations
Mark Plungy
Director, Public Relations
Neil Madle
Director, Corporate Communications/Investor Relations, Europe
+44 (0)7786 526 068
  • Follow Us

Production of any of the material contained herein in any format or media without the express written permission of Varian Medical Systems is prohibited.